ArticleJournal of thoracic disease2025

Assessment of efficacy, safety and survival of tislelizumab as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a real-world data study.

Zhouxv Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.